Literature DB >> 29302077

Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials.

Rury R Holman1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29302077     DOI： 10.1038/nrendo.2017.179

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

Authors:  Rury R Holman; Ruth L Coleman; Juliana C N Chan; Jean-Louis Chiasson; Huimei Feng; Junbo Ge; Hertzel C Gerstein; Richard Gray; Yong Huo; Zhihui Lang; John J McMurray; Lars Rydén; Stefan Schröder; Yihong Sun; Michael J Theodorakis; Michal Tendera; Lynne Tucker; Jaakko Tuomilehto; Yidong Wei; Wenying Yang; Duolao Wang; Dayi Hu; Changyu Pan
Journal:  Lancet Diabetes Endocrinol       Date:  2017-09-13       Impact factor: 32.069

2.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

3.  Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.

Authors:  Kåre I Birkeland; Marit E Jørgensen; Bendix Carstensen; Frederik Persson; Hanne L Gulseth; Marcus Thuresson; Peter Fenici; David Nathanson; Thomas Nyström; Jan W Eriksson; Johan Bodegård; Anna Norhammar
Journal:  Lancet Diabetes Endocrinol       Date:  2017-08-03       Impact factor: 32.069

4.  Prevalence and control of diabetes in Chinese adults.

Authors:  Yu Xu; Limin Wang; Jiang He; Yufang Bi; Mian Li; Tiange Wang; Linhong Wang; Yong Jiang; Meng Dai; Jieli Lu; Min Xu; Yichong Li; Nan Hu; Jianhong Li; Shengquan Mi; Chung-Shiuan Chen; Guangwei Li; Yiming Mu; Jiajun Zhao; Lingzhi Kong; Jialun Chen; Shenghan Lai; Weiqing Wang; Wenhua Zhao; Guang Ning
Journal:  JAMA       Date:  2013-09-04       Impact factor: 56.272

5.  Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.

Authors:  Jelena P Seferovic; Brian Claggett; Sara B Seidelmann; Ellen W Seely; Milton Packer; Michael R Zile; Jean L Rouleau; Karl Swedberg; Martin Lefkowitz; Victor C Shi; Akshay S Desai; John J V McMurray; Scott D Solomon
Journal:  Lancet Diabetes Endocrinol       Date:  2017-03-18       Impact factor: 32.069

6.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

7.  Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.

Authors:  Paul M Ridker; Jean G MacFadyen; Tom Thuren; Brendan M Everett; Peter Libby; Robert J Glynn
Journal:  Lancet       Date:  2017-08-27       Impact factor: 79.321

8.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

9.  Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.

Authors:  John J V McMurray; Hertzel C Gerstein; Rury R Holman; Marc A Pfeffer
Journal:  Lancet Diabetes Endocrinol       Date:  2014-03-13       Impact factor: 32.069

10.  Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.

Authors:  Guangwei Li; Ping Zhang; Jinping Wang; Yali An; Qiuhong Gong; Edward W Gregg; Wenying Yang; Bo Zhang; Ying Shuai; Jing Hong; Michael M Engelgau; Hui Li; Gojka Roglic; Yinghua Hu; Peter H Bennett
Journal:  Lancet Diabetes Endocrinol       Date:  2014-04-03       Impact factor: 32.069
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.